Isolation of Conditionally Immortalized Mouse Glomerular Endothelial Cells with Fluorescent Mitochondria
September 13th, 2022
The article describes the method for isolating conditionally immortalized glomerular endothelial cells from the kidneys of transgenic mice expressing the thermolabile simian virus 40 and photo-activatable mitochondria, PhAMexcised. We describe the procedure for glomeruli isolation from whole kidneys using beads, digestion steps, seeding, and culturing of GECs-CD31 positive.
Overview
This article describes a method for isolating conditionally immortalized glomerular endothelial cells (GECs) from transgenic mice, allowing for the examination of mitochondrial structures in response to various stimuli. Utilizing high yields of GECs, the method serves as a foundation for screening potential therapies for diabetic kidney disease.
Key Study Components
Research Area
- Cell biology
- Diabetic kidney disease research
- Endothelial cell biology
Background
- Immortalized GECs provide a model for studying kidney functions.
- The use of fluorescent mitochondria aids in observing intracellular changes.
- Understanding GEC responses to stimuli can inform therapeutic strategies.
Methods Used
- Isolation and culturing procedures for glomerular endothelial cells
- Transgenic mice expressing fluorescent markers
- Use of collagen IV and magnetic beads for cell selection
Main Results
- A successful isolation protocol yielding viable GECs.
- Verification of cell identity through CD31 positivity and mitochondrial fluorescence.
- Demonstration of the method's application to drug screening in kidney disease.
Conclusions
- The study illustrates a straightforward method for obtaining GECs from mice.
- Results are relevant for understanding endothelial function and developing treatments for kidney diseases.
Frequently Asked Questions
Executive Industry Relevance
Conditionally immortalized mouse glomerular endothelial cells (GECs) with fluorescent mitochondria provide a robust, scalable platform for dissecting mitochondrial dynamics in disease-relevant endothelial systems. This capability enables predictive interrogation of mitochondrial structure-function relationships under pathophysiological stimuli, directly supporting early-stage target validation and mechanistic de-risking in renal drug discovery. The approach enhances portfolio confidence by enabling high-content screening and live-cell imaging for candidate evaluation in diabetic kidney disease and related indications.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables mechanistic interrogation of mitochondrial dysfunction in GECs under disease-relevant conditions.
- Supports functional target validation by linking mitochondrial phenotypes to cellular responses.
- Facilitates predictive confidence in pathway selection for renal disease programs.
Screening & Assay Development
- Provides a renewable source of validated GECs for compound screening and phenotypic assays.
- Enables quantitative, live-cell imaging of mitochondrial fission, fusion, and distribution events.
- Supports assay standardization and reproducibility through stable fluorescent markers.
Translational & Preclinical Research
- Aligns in vitro mitochondrial phenotypes with disease-relevant cellular endpoints.
- Enables continuity from discovery through preclinical validation by supporting functional studies of candidate molecules.
- Reduces translational risk by modeling key aspects of glomerular endothelial dysfunction.
Pipeline & Workflow Integration
This method integrates into the discovery-to-preclinical continuum by providing a platform for hypothesis testing, compound screening, and mechanistic studies in renal endothelial biology.
- Discovery Biology: Supports hypothesis-driven analysis of mitochondrial dynamics and their impact on GEC function.
- Screening: Delivers assay-ready, reproducible cell systems for evaluating small molecule effects on mitochondrial structure.
- Analytics: Enables quantitative measurement of mitochondrial morphology and live imaging outputs for comparative analysis.
- Translational Research: Bridges in vitro findings to disease-relevant mechanisms in glomerular pathophysiology.
- Enterprise Reuse: Establishes a reusable, scalable cell platform for ongoing renal and mitochondrial research initiatives.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in mitochondrial targets and reduces mechanistic ambiguity in renal disease models.
- Operational Value: Standardizes cell sourcing and imaging workflows, improving reproducibility and scalability.
- Strategic Value: Enables informed go/no-go decisions and capital-efficient advancement of renal drug candidates.
- Portfolio Impact: Supports risk-adjusted prioritization by providing robust, disease-relevant cellular readouts.
Implementation Considerations
- Requires expertise in primary cell isolation, transgenic mouse handling, and live-cell imaging.
- Needs access to fluorescence microscopy and cell culture infrastructure.
- Demands rigorous sterilization and workflow standardization to prevent contamination.
- Adaptation to other endothelial or disease models may require protocol optimization.
- Cell heterogeneity and selection steps must be carefully managed for assay consistency.
